Skip to main content

Melanoma Clinical Trials

Review the melanoma clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 255

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Nivolumab in Combination with Relatlimab in Treating Patients with Active Melanoma Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Melphalan via Percutaneous Hepatic Perfusion followed by Tebentafusp for the Treatment of Uveal Melanoma Metastatic to the Liver
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Neoadjuvant Anti-PD-L1 Immunotherapy for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Axitinib and Ipilimumab for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Relatlimab, Nivolumab, and Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma with Asymptomatic or Symptomatic Brain Metastases
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
High-Dose Interleukin-2, Ipilimumab and Nivolumab for the Treatment of Patients with Stage III-IV Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Ipilimumab and Nivolumab before Surgery for the Treatment of Recurrent, High Risk, Resectable Stage IIIB-IV Metastatic Melanoma (NeoRelapse)
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial
Status: Active
Location: 2 locations
Nivolumab plus Axitinib for the Treatment of Stage III or IV Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Single- or Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Combined Immunotherapy with Ipilimumab and Nivolumab or Nivolumab and Relatlimab and Radiation Therapy before Surgery for the Treatment of Sinonasal and Anorectal Melanoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Ipilimumab in Combination with Relatlimab and Nivolumab for the First Line Therapy in Patients with Stage III-IV Unresectable or Metastatic Melanoma, TRINITY Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Clinical Trial Evaluating the Safety and Preliminary Effectiveness of HEPZATO with Immunotherapy in Patients with Metastatic Melanoma and Liver Metastasis
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Nivolumab and Hydroxychloroquine or Nivolumab, Ipilimumab, and Hydroxychloroquine for the Treatment of Stage III-IV Melanoma
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Dapansutrile and Pembrolizumab for the Treatment of Refractory or Recurrent Advanced Melanoma, DREAM Study
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Duvelisib in Combination with Nivolumab for Treatment of Unresectable Stage IIIB-IV Melanoma
Status: Active
Location: 2 locations
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Tebentafusp-tebn in Combination with Liver-Directed Therapies (TACE and IE) for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Lymphodepletion Chemotherapy, CD40L-41BBL-Augmented Tumor Infiltrating Lymphocytes, and Interleukin-2 for the Treatment of Advanced, Unresectable, and Metastatic Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland